Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) released its quarterly earnings data on Thursday. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.14), Zacks reports.
Aptevo Therapeutics Stock Performance
Shares of Aptevo Therapeutics stock remained flat at $1.47 during midday trading on Friday. 1,199,289 shares of the company traded hands, compared to its average volume of 2,424,141. The business has a 50-day moving average price of $1.55 and a two-hundred day moving average price of $3.58. The stock has a market capitalization of $4.83 million, a PE ratio of 0.00 and a beta of 5.93. Aptevo Therapeutics has a 52-week low of $1.32 and a 52-week high of $298.00.
Wall Street Analyst Weigh In
A number of research firms have commented on APVO. Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Wednesday. Roth Capital upgraded shares of Aptevo Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 16th. Wall Street Zen raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Zacks Research raised shares of Aptevo Therapeutics to a “hold” rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aptevo Therapeutics presently has an average rating of “Hold”.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- What is the Nasdaq? Complete Overview with History
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
- Short Selling – The Pros and Cons
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
- Investing in the High PE Growth Stocks
- Qualcomm Earnings Surprise Wall Street—Here’s What Q4 Could Deliver
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
